Eric Lefkofsky: CEO of Tempus
Eric Lefkofsky grew up in the business center of Michigan, in the city of Southfield. After high school he attended the University of Michigan, where he graduated with honors in 1991. Lefkofsky (http://faculty.chicagobooth.edu/eric.lefkofsky/portfolio.html) then continued his education at the University of Michigan Law School and received his Juris Doctor in 1993.
Lefkofsky is now an American entrepreneur and co-founder and CEO of Tempus. Tempus uses Big Data he assist physicians to tailor cancer treatment to patients based on their own genetic profiles. Tempus is partnered with Northwestern University cancer center, and the top genetics researcher from the University of Chicago, Kevin White. White is now the President of Tempus.
Tempus was created out of the need in the health care industry, to provide physicians with tools needed to analyze data. As doctors treat cancer they need to be molecularly aware. Tools were needed to assist them in making decisions in real time clinical settings. Basic infrastructures didn’t exist at most institutions.
The partnership between Tempus and Northwestern’s Lurie Comprehensive Cancer Center changes the way physicians can treat cancer patients. Together they can provide advanced genetic patients profiles. Their software will assist doctors in comparing their profiles with other cancer patients that have similar profiles to help determine the best treatment options. They can see the surgeries and drugs that worked or didn’t work with similar patients. Tempus not only will eliminate the trial and error of test drugs on cancer patients but it will also provide information on clinical trials that may be best suited for the patient.
Eric Lefkofsky understood that treatment results can vary from one person to the next. Cancer types and strands can effect a hand full of patients differently and if the same treatment was used, it would only prove effective on some. Not all cancer patients have the time to trial and error to kind the treatment that will work. Tempus will change that, with its ability to create personal medicine with the use of gene-sequencing and data analysis.
The partnership is ideal in the treatment of cancer. The Cancer Center will provide the anonynmized data about the patient profile’s survival rates and treatments used. Tempus will build a large database for physicians to access to gather the information needed to treat their patient.
More for Lefkofsky here: